Meet the Researcher: Andreas Bader, Triumvira Immunologics
Drug Discovery World
JUNE 14, 2023
We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours. ADCs have made a lot of headway, a lot of successes. I’ve been with a company for more than five years now. We’ve been working on the technology for many years.
52 
Let's personalize your content